A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 plus Chemotherapy (CAPOX or mFOLFOX6) with Pembrolizumab vs Placebo plus Chemotherapy with or without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive

Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Dual endpoints: ● OS, defined as the time from the date of randomization until the documented date of death from any cause ● PFS, defined as the time from the date of randomization until the date of radiographic disease progression (per RECIST V1.1 by BICR) or death from any cause, whichever is earlier

● ORR per RECIST V1.1 by BICR ● DCR per RECIST V1.1 by BICR ● DOR per RECIST V1.1 by BICR, PFS per RECIST V1.1 by investigator assessment, ● ORR per RECIST V1.1 by investigator assessment ● DCR per RECIST V1.1 by investigator assessment ● DOR per RECIST V1.1 by investigator assessment, Safety and tolerability as evaluated by the following: AEs/SAEs, clinical laboratory tests, vital signs, ECGs, and ECOG performance status, Serum concentrations of ASP2138: Ctrough, Participant-reported symptomatic AEs using: ● FACIT-GP5 ● PRO-CTCAE, HRQoL using additional parameters as measured by EORTC QLQ-C30, EORTC QLQ-OG25 and EQ-5D-5L questionnaires, Frequency of ADA-positive participants against ASP2138

No related papers found yet.